Allogene Therapeutics
Shanshan Lang is a Principal Scientist at Allogene Therapeutics, with a focus on leading pre-clinical studies for next-generation BCMA CAR T cell therapy, particularly involving a novel rejection-mitigating modification targeting CD70+ alloreactive T cells. Prior to this role, Shanshan served as a Postdoctoral Researcher at the University of California, San Francisco, optimizing antibodies for therapeutic applications and enhancing production methods for bi-specific and multi-specific antibodies. Earlier research experiences include investigations at The Scripps Research Institute into the mechanisms of broadly neutralizing antibodies against influenza viruses and improvements in gene delivery efficiency of lentivirus in hematopoietic stem cells. Shanshan began a research career as a Research Assistant at Xiamen University, focusing on TNF-α sensitive cells. Shanshan holds a Ph.D. in Biochemistry and Structural Biology from Scripps Research and a Bachelor of Science in Biology from Xiamen University.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.